Patents by Inventor Adrian Leonard Smith
Adrian Leonard Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8772480Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.Type: GrantFiled: November 19, 2012Date of Patent: July 8, 2014Assignee: Amgen Inc.Inventors: Kristin L. Andrews, Yunxin Y. Bo, Shon Booker, Victor J. Cee, Noel D'Angelo, Bradley J. Herberich, Fang-Tsao Hong, Claire L. M. Jackson, Brian Alan Lanman, Hongyu Liao, Longbin Liu, Nobuko Nishimura, Mark H. Norman, Liping H. Pettus, Anthony B. Reed, Adrian Leonard Smith, Seifu Tadesse, Nuria A. Tamayo, Bin Wu, Ryan Wurz, Kevin C. Yang
-
Patent number: 8440674Abstract: The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I wherein R1 is and A1, A2, A3, A4, X, Z, Z?, R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.Type: GrantFiled: June 17, 2011Date of Patent: May 14, 2013Assignee: Amgen Inc.Inventors: Frenel F. De Morin, Jian J. Chen, Elizabeth M. Doherty, Stephen A. Hitchcock, Qi Huang, Joseph L. Kim, Gang Liu, Thomas Nixey, Nick A. Paras, Jeffrey Petkus, Daniel Martin Retz, Adrian Leonard Smith, Jiawang Zhu
-
Patent number: 7858785Abstract: The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.Type: GrantFiled: September 18, 2009Date of Patent: December 28, 2010Assignee: Amgen Inc.Inventors: Adrian Leonard Smith, Paul Edward Brennan, Fenel F. Fils, Gang Liu, Nick A. Paras, Daniel Martin Retz, Elizabeth Rainbeau
-
Patent number: 7786132Abstract: The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.Type: GrantFiled: December 16, 2005Date of Patent: August 31, 2010Assignee: Amgen Inc.Inventors: Adrian Leonard Smith, Paul Edward Brennan, Frenel Fils DeMorin, Gang Liu, Nick A. Paras, Daniel Martin Retz, Elizabeth Rainbeau
-
Publication number: 20100010014Abstract: The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.Type: ApplicationFiled: September 18, 2009Publication date: January 14, 2010Applicant: Amgen Inc.Inventors: Adrian Leonard Smith, Paul Edward Brennan, Frenel Fils DeMorin, Gang Lin, Nick A. Paras, Daniel Martin Retz, Elizabeth Rainbeau
-
Patent number: 7365196Abstract: A class of compounds is disclosed, comprising sulphonamido-substituted bridged bicycloalkyl structures. The compounds are inhibitors of gamma-secretase, and hence are useful in the treatment of and/or prevention of Alzheimer's disease.Type: GrantFiled: March 15, 2001Date of Patent: April 29, 2008Assignees: Merck Sharp & Dohme Ltd., Merck Frosst Canada & Co.Inventors: Patrice Charles Belanger, Ian James Collins, Joanne Claire Hannam, Timothy Harrison, Stephen John Lewis, Andrew Madin, Edward Giles McIver, Alan John Nadin, Joseph George Neduvelil, Mark Steven Shearman, Adrian Leonard Smith, Timothy Jason Sparey, Graeme Irvine Stevenson, Martin Richard Teall
-
Patent number: 7049296Abstract: Urea derivatives of formula I are disclosed: The compounds are inhibitors of ?-secretase, and hence useful in the treatment or prevention of Alzheimer's DiseaseType: GrantFiled: February 28, 2001Date of Patent: May 23, 2006Assignee: Merck Sharp & Dohme Ltd.Inventors: Jose Luis Castro Pineiro, Adrian Leonard Smith, Graeme Irvine Stevenson
-
Publication number: 20040029862Abstract: A class of compounds is disclosed, comprising sulphonamido-substituted bridged bicycloalkyl structures. The compounds are inhibitors of gamma-secretase, and hence are useful in the treatment of and/or prevention of Alzheimer's disease.Type: ApplicationFiled: February 5, 2003Publication date: February 12, 2004Inventors: Patrice Charles Belanger, Ian James Collins, Joanne Claire Hannam, Timothy Harrison, Stephen John Lewis, Andrew Madin, Edward Giles McIver, Alan John Nadin, Joseph George Neduvelil, Mark Steven Shearman, Adrian Leonard Smith, Timothy Jason Sparey, Graeme Irvine Stevenson, Martin Richard Teall
-
Publication number: 20030055005Abstract: 1 Novel urea derivatives of formula I are disclosed: The compounds are inhibitors of &ggr;-secretase, and hence useful in the treatment or prevention of Alzheimer's disease.Type: ApplicationFiled: August 23, 2002Publication date: March 20, 2003Inventors: Jose Luis Castro Pineiro, Adrian Leonard Smith, Graeme Irvine Stevenson
-
Patent number: 6486153Abstract: A class of tryptamine analogues bearing an optionally substituted phenyl nucleus at the 2-position are selective antagonists of the human 5-HT2A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse neurological conditions, including psychotic disorders such as schizophrenia.Type: GrantFiled: March 3, 2000Date of Patent: November 26, 2002Assignee: Merck Sharp & Dohme Ltd.Inventors: Jose Luis Castro Pineiro, Steven Michael Hutchins, Stephen John Lewis, Michael Rowley, Adrian Leonard Smith, Graeme Irvine Stevenson
-
Patent number: 5919947Abstract: The present invention relates to a traceless solid phase process for the preparation of an indole derivative, which comprises the following steps:(1) reaction of an optionally substituted 2-iodoaniline derivative via the nitrogen atom of the NH.sub.2 moiety thereof with a dihydropyran-functionalized polymeric resin under conditions effective to form an aminal linkage;(2) reaction of the tetrahydropyran aminal derivative thereby obtained with an acetylene derivative in the presence of a transition metal catalyst under conditions effective to promote indole formation;(3) treatment of the product thereby obtained with acid, whereby the aminal linkage is cleaved and the desired indole derivative is liberated from the resin; and(4) isolation of the desired indole derivative thereby obtained.Type: GrantFiled: September 2, 1998Date of Patent: July 6, 1999Assignee: Merck Sharp & Dohme Ltd.Inventor: Adrian Leonard Smith
-
Patent number: 5783698Abstract: The present invention relates to a method for the synthesis of 1,3-disubstituted quinazolinedione derivatives which comprises:(a) reacting a haloformate functionalized polystyrene resin with a substituted anthranilic acid derivative under conditions effective to form a urethane-linkage;(b) reacting the product of step (a) with a primary amine under conditions effective to form an anthranilamide derivative;(c) heating the anthranilamide to effect intramolecular cyclization thereby liberating the 1,3-disubstituted quinazolinedione derivative from the resin into solution; and(d) isolating the 1,3-disubstituted quinazolinedione by filtration and solvent removal.Type: GrantFiled: January 7, 1997Date of Patent: July 21, 1998Assignee: Merck Sharp & Dohme LimitedInventor: Adrian Leonard Smith
-
Patent number: 5780475Abstract: Disclosed is a class of 1H-indazole derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, which are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D4 receptor subtype over other dopamine receptor subtypes, and are accordingly, of benefit in the treatment and/or prevention of psychotic disorders, such as schizophrenia, while manifesting fewer side-effects than those associated with classical neuroleptic drugs.Type: GrantFiled: December 29, 1995Date of Patent: July 14, 1998Assignee: Merck, Sharp & Dohme LimitedInventors: Raymond Baker, Janusz Jozef Kulagowski, Paul David Leeson, Adrian Leonard Smith
-
Patent number: 5700809Abstract: Compounds of formula I are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia.Type: GrantFiled: August 29, 1995Date of Patent: December 23, 1997Assignee: Merck Sharp & Dohme, Ltd.Inventors: Paul David Leeson, Adrian Leonard Smith, Mark Peter Ridgill, Raymond Baker, Neil Roy Curtis, Janusz Jozef Kulagowski
-
Patent number: 5665732Abstract: A class of chemical compounds comprising a 1-H-indazole moiety and a substituted heterocyclic moiety, linked via the 3-position of the indazole moiety by a methylene group, are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia. In formula (I) R represents hydrogen or C.sub.1-6 alkyl, Q represents a moiety of formula Qa, Qb, or Qc.Type: GrantFiled: September 8, 1995Date of Patent: September 9, 1997Assignee: Merck, Sharp & Dohme Ltd.Inventors: Raymond Baker, Janusz Jozef Kulagowski, Paul David Leeson, Adrian Leonard Smith